Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma

BACKGROUND. Current guidelines include the use of adjuvant oxaliplatin in clinical stage II or III rectal adenocarcinoma. However, its efficacy is supported by a single phase II trial. We aimed to examine whether oxaliplatin confers survival benefit in this patient population. METHODS. Using the Nat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Margalit, Ofer, Mamtani, Ronac, Kopetz, Scott, Yang, Yu‐Xiao, Lawrence, Yaacov R., Abu‐Gazala, Samir, Reiss, Kim A., Golan, Talia, Halpern, Naama, Aderka, Dan, Giantonio, Bruce, Shacham‐Shmueli, Einat, Boursi, Ben
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Inc. 2019
Soggetti:
Gastrointestinal Cancer
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693732/
https://ncbi.nlm.nih.gov/pubmed/30696723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0333
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi